DTU Publications (2020-2023)

Live to eat and eat to live longer.

Adler A. and Saksena R., (2023), Nat Food, 4, 1029 - 1030

Comparison of medical resources and costs among patients with coronary heart disease and impaired glucose tolerance in the Acarbose Cardiovascular Evaluation trial.

Morrow LM. et al, (2024), J Diabetes, 16

Orthostatic Hypotension, Hypertension Treatment, and Cardiovascular Disease: An Individual Participant Meta-Analysis.

Juraschek SP. et al, (2023), JAMA, 330, 1459 - 1471

Timing of SGLT2i initiation after acute myocardial infarction.

von Lewinski D. et al, (2023), Cardiovasc Diabetol, 22

Aetiology of Type 2 diabetes in people with a 'normal' body mass index: testing the personal fat threshold hypothesis.

Taylor R. et al, (2023), Clin Sci (Lond), 137, 1333 - 1346

Mitochondrial metabolites predict adverse cardiovascular events in individuals with diabetes.

Regan JA. et al, (2023), JCI Insight, 8

Assessment of Cardiac Energy Metabolism, Function, and Physiology in Patients With Heart Failure Taking Empagliflozin: The Randomized, Controlled EMPA-VISION Trial.

Hundertmark MJ. et al, (2023), Circulation, 147, 1654 - 1669

Time-dependent event accumulation in a cardiovascular outcome trial of patients with type 2 diabetes and established atherosclerotic cardiovascular disease.

Bethel MA. et al, (2023), Cardiovasc Diabetol, 22

Association of osteocalcin, osteoprotegerin, and osteopontin with cardiovascular disease and retinopathy in type 2 diabetes.

Maddaloni E. et al, (2023), Diabetes Metab Res Rev, 39

11β-HSD1 inhibition in men mitigates prednisolone-induced adverse effects in a proof-of-concept randomised double-blind placebo-controlled trial.

Othonos N. et al, (2023), Nat Commun, 14

Teplizumab approval for type 1 diabetes in the USA.

Beran D. et al, (2023), Lancet Diabetes Endocrinol, 11, 78 - 80

Joint longitudinal and time-to-event modelling compared with standard Cox modelling in patients with type 2 diabetes with and without established cardiovascular disease: An analysis of the EXSCEL trial.

Oulhaj A. et al, (2023), Diabetes Obes Metab, 25, 1261 - 1270

Impact of baseline kidney function on the effects of sodium-glucose co-transporter-2 inhibitors on kidney and heart failure outcomes: A systematic review and meta-analysis of randomized controlled trials.

Maddaloni E. et al, (2023), Diabetes Obes Metab, 25, 1341 - 1350

Sex differences in the complications, care and clinical outcomes of patients with type 2 diabetes in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).

Green JB. et al, (2023), Diabetes Obes Metab, 25, 1473 - 1484

Patient stratification for determining optimal second-line and third-line therapy for type 2 diabetes: the TriMaster study.

Shields BM. et al, (2023), Nat Med, 29, 376 - 383

Patient preference for second- and third-line therapies in type 2 diabetes: a prespecified secondary endpoint of the TriMaster study.

Shields BM. et al, (2023), Nat Med, 29, 384 - 391

What, Where, and How to Collect Real-World Data and Generate Real-World Evidence to Support Drug Reimbursement Decision-Making in Asia: A reflection Into the Past and A Way Forward.

Kc S. et al, (2023), Int J Health Policy Manag, 12

DTU Publications 2020-2023

2023